55.03
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché MLTX Giù?
Forum
Previsione
Precedente Chiudi:
$55.74
Aprire:
$55.63
Volume 24 ore:
382.56K
Relative Volume:
0.76
Capitalizzazione di mercato:
$3.49B
Reddito:
-
Utile/perdita netta:
$-145.21M
Rapporto P/E:
-23.93
EPS:
-2.3
Flusso di cassa netto:
$-140.12M
1 W Prestazione:
+1.57%
1M Prestazione:
+20.26%
6M Prestazione:
+20.42%
1 anno Prestazione:
+20.73%
Moonlake Immunotherapeutics Stock (MLTX) Company Profile
Nome
Moonlake Immunotherapeutics
Settore
Industria
Telefono
41 41 510 8022
Indirizzo
DORFSTRASSE 29, ZUG
Confronta MLTX con altri titoli
Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
---|---|---|---|---|---|---|
![]()
MLTX
Moonlake Immunotherapeutics
|
55.03 | 3.54B | 0 | -145.21M | -140.12M | -2.30 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
472.27 | 120.73B | 11.10B | -988.90M | -1.26B | -3.92 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
564.64 | 61.80B | 14.09B | 4.50B | 2.96B | 39.28 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
328.00 | 42.46B | 2.35B | -269.70M | -75.39M | -2.09 |
![]()
ARGX
Argen X Se Adr
|
591.74 | 35.22B | 2.58B | 1.06B | -1.28B | 16.33 |
![]()
ONC
Beone Medicines Ltd Adr
|
296.46 | 31.99B | 3.81B | -644.79M | -669.77M | -6.24 |
Moonlake Immunotherapeutics Stock (MLTX) Upgrades & Downgrades
Data | Azione | Analista | Modifica della valutazione |
---|---|---|---|
2025-05-19 | Aggiornamento | Wolfe Research | Peer Perform → Outperform |
2025-03-18 | Iniziato | RBC Capital Mkts | Outperform |
2025-01-17 | Aggiornamento | Goldman | Neutral → Buy |
2024-11-05 | Ripresa | Wedbush | Outperform |
2024-08-26 | Downgrade | Wolfe Research | Outperform → Peer Perform |
2024-06-25 | Iniziato | Oppenheimer | Outperform |
2024-04-02 | Iniziato | Goldman | Neutral |
2024-02-15 | Iniziato | Wolfe Research | Outperform |
2023-12-08 | Iniziato | Citigroup | Buy |
2023-11-02 | Iniziato | Stifel | Buy |
2023-09-14 | Downgrade | Bryan Garnier | Buy → Neutral |
2023-08-31 | Iniziato | Needham | Buy |
2023-06-15 | Iniziato | Barclays | Equal Weight |
2023-05-01 | Iniziato | Guggenheim | Buy |
2023-03-22 | Iniziato | Wedbush | Outperform |
2023-03-09 | Iniziato | BTIG Research | Buy |
2023-02-14 | Iniziato | Cantor Fitzgerald | Overweight |
2023-02-02 | Iniziato | Bryan Garnier | Buy |
2022-11-11 | Iniziato | Jefferies | Buy |
2022-08-25 | Iniziato | SVB Leerink | Outperform |
2022-07-21 | Iniziato | H.C. Wainwright | Buy |
2022-07-07 | Iniziato | Cowen | Outperform |
Mostra tutto
Moonlake Immunotherapeutics Borsa (MLTX) Ultime notizie
MoonLake Immunotherapeutics Stock Analysis and ForecastUnprecedented market success - Autocar Professional
What analysts say about MoonLake Immunotherapeutics stockTurbocharged investment results - Autocar Professional
Podcast: Inside MoonLake’s Fast-Track Vision And $500m Deal - insights.citeline.com
MoonLake Immunotherapeutics: Promising Phase 3 Trials and Market Potential for Sonelokimab - TipRanks
What drives MoonLake Immunotherapeutics stock priceExplosive capital gains - jammulinksnews.com
Is MoonLake Immunotherapeutics a good long term investmentSky-high return potential - jammulinksnews.com
(MLTX) Trading Advice - news.stocktradersdaily.com
MoonLake Immunotherap Scores Relative Strength Rating Upgrade; Hits Key Benchmark - Investor's Business Daily
What makes MoonLake Immunotherapeutics stock price move sharplyFree Investment Risk Control - Newser
Why MoonLake Immunotherapeutics stock attracts strong analyst attentionFree Stock Market Insider Analysis - Newser
How MoonLake Immunotherapeutics stock performs during market volatilityQuick Profit Idea Stream - Newser
MoonLake Immunotherap Reaches 80-Plus Relative Strength Rating Benchmark - Investor's Business Daily
Merck made $3B+ offer for MoonLake earlier this yearreport - MSN
MoonLake Immunotherap Getting Closer To Key Technical Benchmark - Investor's Business Daily
MoonLake Immunotherapeutics Director Makes a Major Stock Move! - TipRanks
Merck Offers Over $3 Billion to Acquire MoonLake Immunotherapeutics Amid Biotech Sector Challenges - geneonline.com
Merck Offers Over $3 Billion to Acquire MoonLake Immunotherapeutics Amid Sector Challenges - geneonline.com
Merck Offers Over $3 Billion to Acquire MoonLake Immunotherapeutics Amid Biotech Sector Developments - geneonline.com
Learn to Evaluate (MLTX) using the Charts - news.stocktradersdaily.com
Merck Offers Over $3 Billion to Acquire MoonLake Immunotherapeutics Amid Industry Developments - geneonline.com
MoonLake Immunotherapeutics’ SWOT analysis: nanobody firm’s stock poised for pivotal phase III data - Investing.com South Africa
Merck's Keytruda Secures FDA Nod For Head And Neck Cancer As First Immunotherapy For Use Around Surgery - Benzinga
IIH interview: Matthias Bodenstedt discusses MoonLake’s capital raising journey, the appeal of SLK and plans for the future - Investors in Healthcare
MoonLake Immunotherapeutics: Strategic Positioning and Promising Clinical Developments Drive Buy Rating - TipRanks
Merck Offers Over $3 Billion to Acquire MoonLake Immunotherapeutics Amid Focus on Inflammatory Disease Treatments - geneonline.com
MoonLake Immunotherapeutics Catapults On Rumored Merck Takeover - MSN
Merck Offers Over $3 Billion to Acquire MoonLake Immunotherapeutics Amid Biotech Sector Focus - geneonline.com
MoonLake Immunotherapeutics (MLTX) Hosts Investor Meetings Amid Merger Speculation | MLTX Stock News - GuruFocus
Stat’s Feuerstein says ‘no imminent acquisition’ of MoonLake Immunotherapeutics - TipRanks
Moonlake Immunotherapeutics Azioni (MLTX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):